Low thrombin generation in postmenopausal women using estetrol

References

• Manson JE, Kaunitz AM. Menopause management–getting clinical care back on track. N Engl J Med. 2016;374(9):803–806. doi: 10.1056/NEJMp1514242.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi: 10.1136/bmj.k4810.
   PubMed Web of Science ®Google Scholar
• Rovinski D, Ramos RB, Fighera TM, et al. Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis. Thromb Res. 2018;168:83–95. doi: 10.1016/j.thromres.2018.06.014.
   PubMed Web of Science ®Google Scholar
• Sundell M, Spetz Holm AC, Fredrikson M, et al. Pulmonary embolism in menopausal hormone therapy: a population-based register study. Climacteric. 2022;25(6):615–621. Dec doi: 10.1080/13697137.2022.2127352.
   PubMed Web of Science ®Google Scholar
• Blondon M, van Hylckama Vlieg A, Wiggins KL, et al. Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers. J Thromb Haemost. 2014;12(6):879–886. doi: 10.1111/jth.12560.
   PubMed Web of Science ®Google Scholar
• Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174(1):25–31. doi: 10.1001/jamainternmed.2013.11074.
   PubMed Web of Science ®Google Scholar
• Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015;82(3):304–307. doi: 10.1016/j.maturitas.2015.06.040.
   PubMed Web of Science ®Google Scholar
• Harrington LB, Blondon M, Cushman M, et al. The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women. Menopause. 2017;24(4):360–370. doi: 10.1097/GME.0000000000000777.
   PubMed Web of Science ®Google Scholar
• Kremers RM, Peters TC, Wagenvoord RJ, et al. The balance of pro- and anticoagulant processes underlying thrombin generation. J Thromb Haemost. 2015;13(3):437–447. doi: 10.1111/jth.12798.
   PubMed Web of Science ®Google Scholar
• Brenner B. Haemostatic changes in pregnancy. Thromb Res. 2004;114(5–6):409–414. doi: 10.1016/j.thromres.2004.08.004.
   PubMed Web of Science ®Google Scholar
• de Visser MC, van Hylckama Vlieg A, Tans G, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost. 2005;3(7):1488–1494. doi: 10.1111/j.1538-7836.2005.01430.x.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Morimont L, Bouvy C. Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk. Semin Thromb Hemost. 2020;46(8):872–886. doi: 10.1055/s-0040-1714140.
   PubMedGoogle Scholar
• Morimont L, Haguet H, Dogné J-M, et al. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol. 2021;12:769187. doi: 10.3389/fendo.2021.769187.
   PubMed Web of Science ®Google Scholar
• Canonico M, Alhenc-Gelas M, Plu-Bureau G, et al. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause. 2010;17(6):1122–1127. doi: 10.1097/gme.0b013e3181e102eb.
   PubMed Web of Science ®Google Scholar
• Eilertsen AL, Dahm AEA, Høibraaten E, et al. Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment. Blood Coagul Fibrinolysis. 2019;30(1):17–23. doi: 10.1097/MBC.0000000000000784.
   PubMed Web of Science ®Google Scholar
• Morimont L, Dogné J-M, Douxfils J. Letter to the editors-in-Chief in response to the article of Abou-Ismail, et al. Entitled "Estrogen and thrombosis: a bench to bedside review" (thrombosis research 192 (2020) 40-51). Thrombosis Research. 2020;193:221–223. doi: 10.1016/j.thromres.2020.08.006.
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4–15. doi: 10.1159/000071636.
   PubMedGoogle Scholar
• Douxfils J, Morimont L, Delvigne AS, et al. Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need. Clin Chem Lab Med. 2020;58(2):294–305. doi: 10.1515/cclm-2019-0471.
   PubMed Web of Science ®Google Scholar
• van Hylckama Vlieg A, Christiansen SC, Luddington R, et al. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol. 2007;138(6):769–774. doi: 10.1111/j.1365-2141.2007.06738.x.
   PubMed Web of Science ®Google Scholar
• Lutsey PL, Folsom AR, Heckbert SR, et al. Peak thrombin generation and subsequent venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE) study. J Thromb Haemost. 2009;7(10):1639–1648. doi: 10.1111/j.1538-7836.2009.03561.x.
   PubMed Web of Science ®Google Scholar
• Reda S, Morimont L, Douxfils J, et al. Can We measure the individual prothrombotic or prohemorrhagic tendency by global coagulation tests? Hamostaseologie. 2020;40(3):364–378. doi: 10.1055/a-1153-5824.
   PubMedGoogle Scholar
• Bucciarelli P, Mannucci PM. The hemostatic system through aging and menopause. Climacteric. 2009;12(Suppl 1):47–51. doi: 10.1080/13697130903006365.
   PubMedGoogle Scholar
• Bagot CN, Marsh MS, Whitehead M, et al. The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. J Thromb Haemost. 2010;8(8):1736–1744. doi: 10.1111/j.1538-7836.2010.03953.x.
   PubMed Web of Science ®Google Scholar
• Blondon M, Wiggins KL, Van Hylckama Vlieg A, et al. Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population-based, case-control study. Br J Haematol. 2013;163(3):418–420. doi: 10.1111/bjh.12508.
   PubMed Web of Science ®Google Scholar
• Bauer KA, Weiss LM, Sparrow D, et al. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study. J Clin Invest. 1987;80(6):1527–1534. doi: 10.1172/JCI113238.
   PubMed Web of Science ®Google Scholar
• Abot A, Fontaine C, Buscato M, et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328–1346. doi: 10.15252/emmm.201404112.
   PubMed Web of Science ®Google Scholar
• Arnal JF, Lenfant F, Metivier R, et al. Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications. Physiol Rev. 2017;97(3):1045–1087. doi: 10.1152/physrev.00024.2016.
   PubMed Web of Science ®Google Scholar
• Foidart JM, Gaspard U, Pequeux C, et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: Brinton RD, Genazzani AR, Simoncini T, et al. editors. Sex steroids’ effects on brain, heart and vessels. ISGE series. Cham: Springer International Publishing; 2019. p. 169–195.
   Google Scholar
• Gérard C, Arnal J-F, Jost M, et al. Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. Expert Rev Clin Pharmacol. 2022;15(2):121–137. doi: 10.1080/17512433.2022.2054413.
   PubMed Web of Science ®Google Scholar
• Gaspard U, Taziaux M, Jost M, et al. A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol (E4) in postmenopausal participants (E4 relief): part 2. Vaginal cytology, genitourinary syndrome of menopause and health-related quality of life. Menopause. 2022;30(5):480–489. doi: 10.1097/GME.0000000000002167.
   Web of Science ®Google Scholar
• Coelingh Bennink HJT, Verhoeven C, Zimmerman Y, et al. Pharmacodynamic effects of the fetal estrogen estetrol in postmenopausal women: results from a multiple-rising-dose study. Menopause. 2017;24(6):677–685. doi: 10.1097/GME.0000000000000823.
   PubMed Web of Science ®Google Scholar
• Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety. Menopause. 2020;27(8):848–857. Aug doi: 10.1097/GME.0000000000001561.
   PubMed Web of Science ®Google Scholar
• Utian WH, Gaspard U, Jost M, et al. Estetrol, the next generation of hormone therapy: results of a phase 2b dose-finding study in postmenopausal women (E4 relief). San Diego, CA: NAMS; 2018.
   Google Scholar
• Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102(6):396–402. Dec doi: 10.1016/j.contraception.2020.08.015.
   PubMed Web of Science ®Google Scholar
• Douxfils J, Lobo R, Taziaux M, et al. Estetrol (E4) is a native fetal estrogen that does not modify coagulation markers in postmenopausal women and maintains sensitivity to activated protein C (APC). Maturitas. 2021;152:69. doi: 10.1016/j.maturitas.2021.08.013.
   Google Scholar
• Douxfils J, Gaspard U, Taziaux M, et al. Impact of estetrol (E4) on hemostasis, metabolism, and bone turnover in postmenopausal women. Climacteric. 2022;26(1):55–63. doi: 10.1080/13697137.2022.2139599.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline, Third Edition. Wayne (PA): Clinical and Laboratory Standards Institute; 2010.
   Google Scholar
• Canonico M. Hormone therapy and hemostasis among postmenopausal women: a review. Menopause. 2014;21(7):753–762. doi: 10.1097/GME.0000000000000296.
   PubMed Web of Science ®Google Scholar
• Tripodi A, Martinelli I, Chantarangkul V, et al. The endogenous thrombin potential and the risk of venous thromboembolism. Thromb Res. 2007;121(3):353–359. doi: 10.1016/j.thromres.2007.04.012.
   PubMed Web of Science ®Google Scholar
• Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003;23(9):1671–1676. doi: 10.1161/01.ATV.0000087141.05044.1F.
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997;17(11):3071–3078. doi: 10.1161/01.atv.17.11.3071.
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–1231. doi: 10.1136/bmj.39555.441944.BE.
   PubMed Web of Science ®Google Scholar
• Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women. Arterioscler Thromb Vasc Biol. 2003;23(6):1116–1121. doi: 10.1161/01.ATV.0000074146.36646.C8.
   PubMed Web of Science ®Google Scholar
• Morimont L, Jost M, Gaspard U, et al. Low thrombin generation in users of a contraceptive containing estetrol and drospirenone. J Clin Endocrinol Metab. 2022;108(1):135–143. doi: 10.1210/clinem/dgac511.
   PubMedGoogle Scholar
• Scarabin P-Y, Hemker HC, Clément C, et al. Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause. 2011;18(8):873–879. doi: 10.1097/gme.0b013e31820eee88.
   PubMed Web of Science ®Google Scholar
• Post MS, Rosing J, Van Der Mooren MJ, et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol. 2002;119(4):1017–1023. doi: 10.1046/j.1365-2141.2002.03957.x.
   PubMed Web of Science ®Google Scholar
• Post MS, van der Mooren MJ, van Baal WM, et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol. 2003;189(5):1221–1227. doi: 10.1067/s0002-9378(03)00599-4.
   PubMed Web of Science ®Google Scholar
• Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982;144(5):511–518. doi: 10.1016/0002-9378(82)90218-6.
   PubMed Web of Science ®Google Scholar
• Stumpf PG. Pharmacokinetics of estrogen. Obstet Gynecol. 1990;75(Supplement):15S. discussion 15S-17S. doi: 10.1097/00006250-199004001-00003.
   PubMedGoogle Scholar
• Ryan KJ, Engel LL. The interconversion of estrone and estradiol by human tissue slices. Endocrinology. 1953;52(3):287–291. doi: 10.1210/endo-52-3-287.
   PubMed Web of Science ®Google Scholar
• Tebbens M, Heijboer AC, T’Sjoen G, et al. The role of estrone in feminizing hormone treatment. J Clin Endocrinol Metab. 2022;107(2):e458–e466. doi: 10.1210/clinem/dgab741.
   PubMed Web of Science ®Google Scholar
• Di Bitondo R, Hall AJ, Peake IR, et al. Oestrogenic repression of human coagulation factor VII expression mediated through an oestrogen response element sequence motif in the promoter region. Hum Mol Genet. 2002;11(7):723–731. doi: 10.1093/hmg/11.7.723.
   PubMed Web of Science ®Google Scholar
• Oger E, Lacut K, Mercier B, et al. Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study. Thromb Res. 2007;119(4):433–439. doi: 10.1016/j.thromres.2006.05.002.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(sup1):3–63. doi: 10.1080/13697130500148875.
   PubMed Web of Science ®Google Scholar
• Canonico M, Bouaziz E, Carcaillon L, et al. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab. 2008;93(8):3082–3087. doi: 10.1210/jc.2008-0450.
   PubMed Web of Science ®Google Scholar
• Slater CC, Hodis HN, Mack WJ, et al. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause. 2001;8(3):200–203. doi: 10.1097/00042192-200105000-00009.
   PubMed Web of Science ®Google Scholar
• De Lignieres B, Basdevant A, Thomas G, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab. 1986;62(3):536–541. doi: 10.1210/jcem-62-3-536.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Yue W, Wang JP. Estrogen metabolites and breast cancer. Steroids. 2015;99(Pt A):61–66. doi: 10.1016/j.steroids.2014.08.003.
   PubMedGoogle Scholar
• Jirku H, Kadner S, Levitz M. Pattern of estetrol conjugation in the human. Steroids. 1972;19(4):519–534. doi: 10.1016/s0039-128x(72)80019-9.
   PubMed Web of Science ®Google Scholar
• Pedram A, Razandi M, O’Mahony F, et al. Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling. Sci Signal. 2013;6(276):ra36. doi: 10.1126/scisignal.2004013.
   PubMed Web of Science ®Google Scholar